tara seery, md: mechanisms of action in regorafenib
Published 8 years ago • 327 plays • Length 0:36Download video MP4
Download video MP3
Similar videos
-
0:58
tara seery, md: main adverse events with regorafenib
-
1:00
tara seery, md: regorafenib dose adjustments
-
0:51
tara seery, md: clinical data supporting regorafenib in mcrc
-
0:58
tara seery, md: reinitiating regorafenib in patients with mcrc
-
0:31
tara seery, md; chemotherapy as a possible option
-
1:01
tara seery, md: fourth-line therapy in mcrc
-
1:12
tanios bekaii-saab, md: mechanisms of action in regorafenib
-
1:07
tara seery, md: impact of third-line therapy
-
0:46
tara seery, md: clinical data supporting trifluradine-tipiracil
-
0:22
tara seery, md: kras status in mcrc
-
1:20
tanios bekaii-saab, md: clinical data supporting regorafenib in mcrc
-
9:34
regorafenib in colorectal cancer
-
0:28
tanios bekaii-saab, md: reinitiating regorafenib in patients with mcrc
-
1:28
surivival benefit of regorafenib in correct and concur trials
-
0:58
the significance of the resorce trial in hcc
-
1:03
dr. musher discusses the role of regorafenib in advanced hcc
-
2:02
dr. bruix discusses the application of regorafenib in hcc
-
0:57
choosing between tas-102 and regorafenib in colorectal cancer
-
1:21
tanios bekaii-saab, md: regorafenib dose adjustments